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ABSTRACT
NOVEL UNCHARGED LOCAL ANESTHETICS
Rob Hussain, Ph.D.
Department of Biological Sciences
Northern Illinois University, 2014
Richard Hahin, Director

Bupivacaine is among the most widely used local anesthetics (LAs) for invasive procedures and
postoperative pain relief because of its long duration of action and potency. Bupivacaine carries a risk for
cardiotoxicity and the relationship between its structure and its anesthetic action is incompletely known.
This study was designed to characterize how changes in the aromatic ring of a class of carbamoyl piperidines (CPs), which structurally resemble bupivacaine, alter anesthetic action. In most of the CPs, the carbonyl carbon is directly bonded to the piperidine nitrogen (called the 1N position); bupivacaine, in contrast, features a 2N motif. The major objective was to determine how the placement and number of methyl
group substitutions on the aromatic rings of the CPs alters potency and reversibility of anesthetic block.
With this information, structural changes in the CPs could be suggested to design a new and safer LA.
The blocking action of the CPs was investigated using a modified single-sucrose gap technique
for recording action potentials from frog and rat nerve. To assay whether CPs preferentially block open
sodium channels, CP blocking experiments were conducted on nerves pretreated with an alpha-scorpion
toxin. The slopes of the dose-response relationships of the CPs varied, which is consistent with the hypothesis that some CPs may bind to more than one site on sodium channels. The potency of CPs with
two methyl groups is maximized when the methyl groups are separated by two positions. Potent CPs tend
to result in smaller recoveries from block once the CPs are removed from the nerve. Phasic blocking potency increases as hydrophobicity increases. The CPs did not preferentially block open Na channels, as
some LAs do. There was no significant difference in tonic blocking potencies of the CPs when applied to
frog or rat nerves, suggesting that their action might be similar in humans. Among the 1N CPs, the half
maximal blocking dose is predicted as a function of pKa, molar volume, and methyl group positions.
However, the half maximal blocking dose for the 2N CPs depends only on pKa. These CPs might present
less risk for toxicity than bupivacaine.
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CHAPTER 1
INTRODUCTION

Anesthesia, the absence of sensation, is clinically induced to reduce the sensation of pain for
surgery. While general anesthetics are used to produce unconsciousness, skeletal muscle relaxation, and
analgesia, local anesthetics (LAs) are used to produce anesthesia over more localized regions. Bupivacaine, among the most widely used LA for invasive procedures and postoperative analgesia, is known for
its long duration of action and considerable potency. A major aim of this work was to see how the positions of methyl group substituents in the aromatic ring of a class of carbamoyl piperidines (CPs), which
structurally resemble bupivacaine, alter their anesthetic action.

LA Structure

Local anesthetics, such as bupivacaine, lidocaine, and benzocaine, usually possess a tertiary
amine portion and a substituted aromatic group (see Figure 1). These domains are connected by an amide or ester group (Shandler, 1965). Local anesthetics interact with many proteins, such as calmodulinsensitive proteins (Volpi et al., 1981), the sodium (Na)-potassium (K) ATPase (Sholz, 2002), magnesiumand calcium-dependent ATPases (Roufogalis, 1973), and various ion channels (Sholz, 2002). Local anesthetics are thought to produce anesthesia primarily by blocking voltage-gated Na channels (Na channels)
that play key roles in initiating and propagating nerve impulses called action potentials (APs).
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bupivacaine

lidocaine

benzocaine

Figure 1. Structures of bupivacaine, lidocaine, and benzocaine.

Na Channels

Na channels are proteins that consist of an approximately 260-kDa α-subunit (see Figure 2) in
association with β-subunits (Catterall, 2012). The α-subunit is composed of homologous domains D1
through D4, each containing membrane-spanning segments S1 through S6 (Catterall, 2012) (see Figure
2). The domains of the α-subunit are arranged to form a central pore, where LAs are thought to interact
(Hanck et al., 2009; Li et al., 1999). Na channels transition between closed, open, and inactivated states
in a voltage-dependent manner. When the membrane potential of excitable cells increases to some
+

threshold value, Na channels open and conduct Na into the cell, which depolarizes the membrane and
produces the upstroke of an AP.
When a Na channel opens, the positive residues of each S 4, called the voltage sensor, move extracellularly (Marban, Yamagishi, and Tomaselli, 1998) briefly and rapidly. Shortly after the initiation of an
AP, virtually all Na channels inactivate by transitioning into a non-conducting state. As the membrane
voltage repolarizes during the AP downstroke, Na channels are able to convert to activatable closed
states (Armstrong, 2006) to allow successive APs to be initiated.
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Figure 2. Alpha subunit of a voltage-gated Na channel. Alpha subunit of a Na channel showing domains
D1-D4, each with transmembrane segments S1-S6. A. Scorpion α-toxins bind to a site on the S3-S4 linker
of D4. B. D4S6 has phenyl group-containing residues like F1579 and Y1766 in human Na V1.5, which are
part of the LA-binding domain(s).

Many substances interact with Na channels. Tetrodotoxin and saxitoxin are potent toxins produced by Takifugu (Japanese pufferfish) and Gonyaulax (dinoflagellates), respectively, that bind to the
outer vestibule of Na channels, whereas synthetic molecules like LAs, anti-arrhythmics, and anticonvulsants bind to a presumptive LA receptor binding site (Catterall, Goldin, and Waxman, 2005). Na
channels are important modulators of pain processing. TTX-resistant Na channels, for instance, have
been shown to be involved in hyperalgesia following sensory neuron injury (Kerr et al., 2001). PPPA (2[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide) (Ilyin et al., 2006) and neosaxitoxin (Rodriguez-Navarro et al., 2007), both Na channel blockers, have also been shown to effect pain relief. Since
LAs are used to attenuate pain, LA-Na channel interactions are essential to successful anesthesia.
The substituted aromatic groups of LAs are important for producing anesthesia, as these groups
significantly interact with Na channels (Li et al., 1999). Molecular modeling by Lipkind and Fozzard (2010)
suggested that the aromatic groups of the LAs bupivacaine, lidocaine, mepivacaine, and etidocaine interacted primarily with Y1586 of the D4S6 segment of Na channels, which is also the putative major drugbinding site (Catterall, 2012). Kuroda et al. (1996) showed that the aromatic quinoline group of the LA
dibucaine affects inactivation. Kuo, Huang, and Lou (2000) discovered that a number of molecules containing two aromatic groups, including diphenhydramine, phenytoin, and imipramine, selectively bind inac-
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tivated channels. Strother et al. (1977) found that methyl-group substitutions on the aromatic ring of lidocaine influenced both its potency and toxicity.
One major aim of this work was to determine how the structure of the substituted aromatic groups
of the CPs alters AP blocking potency and reversibility of block. Armed with this information, changes in
the bupivacaine structural platform could be made to design new and safer LAs.

Developments That Led to Bupivacaine

Cocaine was first isolated by Gaedcke in 1855 and was regularly employed due to its ability to be
topically applied and produce anesthesia (Finucane, 1999). However, cocaine’s use resulted in convulsion, cerebral excitement, and paralysis. The ester-linked LAs, which includes procaine, were first synthesized in 1905, and were based on cocaine’s structure. While procaine lacked cocaine’s euphoric and addictive qualities, it nevertheless produced symptoms like restlessness, convulsion, respiratory failure, and
cardiac arrest (Raj, 2002). In fact, many LAs produce various excitatory and cardiovascular effects at certain doses and can be particularly toxic if inadvertently administered intravascularly. Significant excitatory
effects of LAs include grand mal convulsion and muscular twitching (Swain, 1996), while cardiovascular
effects included reduced cardiac contractility, increased heart rate, and cardiomyopathies (Schwartz,
Rezkalla, and Kloner, 2012).
The amide-linked LAs, which include lidocaine and bupivacaine, have more favorable chemical
properties than the ester LAs. Lidocaine, synthesized in 1943, was shown to have great stability in solution, fail to produce irritation at the injection site, and was adequate for dentistry (Raj, 2002), relative to
the ester LAs. af Ekenstam et al. (1957) first synthesized bupivacaine (see Figure 3) among other Nalkylated pyrrolidine and piperidine carboxylic acids. Each of these acids featured a carbonyl carbon attached to a pyrrolidine or piperidine group to produce an α-, β-, or γ-amide (see Figure 3). af Ekenstam et
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al. (1957) determined fundamental chemical characteristics related to the toxicity and potency of these
amides. For instance, the α-amides were nearly three times as toxic as the β- and γ-amides (as measured by subcutaneous injections in rats), were nearly 3.5 times as potent as β-amides (as measured by
rat ulnar nerve block), were seven times as potent as γ-amides, had the longest duration of action, and
had among the highest therapeutic indices (af Ekenstam et al., 1957). Bupivacaine, an α-amide, was
among the most toxic, most potent, and longest-lasting of the pyrrolidine- or piperidine carboxylic acidbased LAs. Alkylation of the piperidine nitrogen of bupivacaine increases toxicity; among the α-amides
with the 2,6-dimethylphenyl structure, toxicity increased as the alkyl substituent bonded to the piperidine
nitrogen lengthened in the following order: -CH3, -C2H5,, n-C3H7,, n-C4H9 (af Ekenstam et al., 1957). The
effect of aromatic ring substituents on toxicity depended on the substituent: replacing the 2-methyl group
of 1-ethyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide with chlorine resulted in a compound about
1.5 times as toxic, while substitution of the 2-methyl group of 1-ethyl-N-(2-methylphenyl)piperidine-2carboxamide with the 4-methoxy group resulted in a compound about 1.4 times less toxic (af Ekenstam
et al., 1957).

Figure 3. Structure of bupivacaine, an α-amide. Bupivacaine’s butyl group substituent on its piperidine
nitrogen enhances its potency and toxicity.
Bupivacaine is today’s de facto standard LA for infiltration, spinal, epidural, and caudal anesthesia (WHO Model Prescribing Information). Nevertheless, bupivacaine is potently cardiotoxic and can produce neurotoxic effects upon inadvertent intravascular administration (Finucane, 1999); at certain plasma
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concentrations, bupivacaine has been shown to cause cardiovascular depression, ventricular arrhythmias
and fibrillation, respiratory arrest, and convulsion. Modification of bupivacaine’s structure has already
been shown to reduce toxicity, among other pharmacodynamic changes. Bupivacaine’s S-(-) enantiomer,
levobupivacaine, for instance, was found not only to be less toxic, have a longer duration of action, and
be less potent than racemic bupivacaine (Balser et al., 1996; Morrison et al., 2000). However, ropivacaine, an S-(-) enantiomer with a propyl group substituent on the piperidine nitrogen, carries nearly the
same risk for cardiac arrest as racemic bupivacaine (Morrison et al., 2000). The structure-activity relationship for LAs with bupivacaine’s structural platform is not completely understood.
Most of the CPs in this study are not α-amides like bupivacaine, as the carbonyl carbon is directly
bonded to the piperidine nitrogen and the piperidine nitrogen lacks substitution, which af Ekenstam et al.
(1957) found was associated with toxicity. Consequently, these CPs might present less risk for toxicity
than bupivacaine. The CPs also represent a class of LAs that af Ekenstam et al. (1957) did not synthesize and which have not been evaluated previously for anesthetic action. This work determined several
properties of the CPs that can be understood in the context of LA mechanisms of action.

LAs Modify Na Channel Activation

LAs bind to putative receptor(s) located within the pore of Na channels (Sholz, 2002). Activatable
Na channels can rapidly and reversibly bind LA before inactivating (Butterworth and Strichartz, 1999).
LAs also bind closed and inactivated channel states and promote a longer-lasting inactivated state and
can bind intermediately activated states to interrupt channel activation (Butterworth and Strichartz, 1999;
Muroi and Chanda, 2009; Sheets and Hanck, 2003; Sheets and Hanck, 2007), suggesting that LAs interfere with activation rather than directly occlude the channel pore. Later components of gating currents are
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blocked more than earlier ones in the presence of LAs, leaving earlier activation processes relatively intact (Butterworth and Strichartz, 1999). Some LAs are particularly beneficial because they alter certain Na
channel states preferentially. While LAs block Na channels, some do so with greater potency when Na
channels open more frequently, a phenomenon called use-dependent or phasic block (Strichartz, 1976;
Sholz, 2002; Scheuer, 1999).

Phasic Block by LAs

Tonic block describes channel block at membrane potentials that do not activate Na channels
and cause channels to occupy closed states with greater probability. Tonic block is associated with a decrease in Na current and a hyperpolarizing shift in the voltage dependence of inactivation, but phasic
block is associated with higher-affinity LA-channel binding to open and inactivated channel states (Sholz,
2002). Drugs, such as anticonvulsants and antiarrhythmics, that phasically block Na channels act to suppress high-frequency APs associated with epilepsies and arrhythmias, respectively (Carocci et al., 2010).
Pain syndromes, such as erythromelalgia and paroxysmal extreme pain syndrome (Dabby, 2012), are
associated with ectopic high-frequency Na channel openings that produce a phenomenon called phasic
pain. There are certain advantages to having drugs that are potent phasic channel blockers. For anticonvulsants and antiarrhythmics, phasic block must be sufficient to block Na channels in abnormally depolarized tissue to a greater extent compared to channels in normally polarized tissue.
Phasic block results from the accumulation of LA binding to Na channels as channels open repeatedly in response to successive stimuli, causing increased block. Increasing depolarization duration,
which increases the probability that Na channels are open or inactivated, increases the degree of channel
binding for some LAs (Li et al., 1999). During high-frequency depolarization, there are relatively reduced
periods of hyperpolarization; as hyperpolarization causes channel closing and LAs consequently to disso-
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ciate from channels, reducing hyperpolarization durations produce less LA dissociation and net accumulation of block.
Phasic block is associated with modification of gating currents that result from LA-mediated stabilization of D3S4 and D4S4 in the activated position (Hanck et al., 2009). Several studies suggest that the
aromatic group of a phenylalanine residue in D4S6 (F1759 in NaV1.5) is significant for phasic blocking potency and block of gating currents (Hanck et al., 2009). A tyrosine residue in D 4S6 also affects phasic
block by LAs, but does not affect tonic block (Li et al., 1999). The protonated amine portions of LAs might
interact with residues in D4S6 in open and inactivated channels via cation-pi electron interactions in the
same way tetraethylammonium binds potassium channels or acetylcholinesterase binds nicotinic acetylcholine receptors (Li et al., 1999). Compared to phasic block, tonic block by lidocaine is voltageindependent and is associated with low-affinity channel binding. Hanck et al. (2009) characterizes this
“lipophilic block” by the interaction of uncharged lidocaine with neutral residues in the closed state.
Inactivation is vital for LA binding (Strichartz, 1977); the removal of fast inactivation removes highaffinity channel block due to lidocaine and quaternary LAs (Hanck et al., 2009; Chahine et al., 1992;
Wang et al., 1987; Bennett et al., 1995). Li et al. (1999) suggest LA binding affinity is between 10 to 100
times higher for open and inactivated states than for closed states (Kambouris et al., 1998; Son, Wong,
and Stricharz, 2004). There is significant LA binding to the inactivated state: the half-blocking concentration of lidocaine decreases over one magnitude when channels are inactivated compared to other channel states (Bean, Cohen, and Tsien, 1983). The aromatic moieties of lidocaine and dibucaine are thought
to interact with the inactivation gate of Na channels via pi-pi stacking (Kuroda et al., 2000). Voltage clamp
experiments suggest that an asparagine (N434 in Na v1.4) in D1S6 and a leucine (L1280 in Nav1.4) in D3S6
in inactivated channels interact with bupivacaine (Nau et al., 2003); D1S6 and D3S6 are components of the
putative LA receptor and may be related to inactivation. Additionally, LA binding is considerably affected
by slow inactivation, a state induced by very prolonged depolarization that requires much longer recovery
times than fast inactivation (Khodorov et al., 1976). Balser et al. (1996) found that elimination of slow inactivation inhibits phasic block by lidocaine and that slow-inactivated channels remain blocked longer
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than fast-inactivated channels; they proposed that recovery from slow inactivation potentiates phasic
block.
LA binding of the inactivated state delays a channel’s recovery from inactivation (Chernoff and
Stricharz, 1989; Sheets, Jarecki, and Cummins, 2011; Chevrier, Vijayaragavan, and Chahine, 2004;
Bean, Cohen, and Tsien, 1983) and its return to the closed state, prolonging channel block. Recovery
from inactivation of LA-bound channels is slow. The rate of recovery from inactivation of LA-bound channels might be limited by the slow rate of LA dissociation (Courtney, 1981). Alternatively, recovery from
inactivation could be limited by activation and/or inactivation gates. According to Yeh’s m-gate trapping
hypothesis (1985), LA dissociation requires an open activation gate, which occurs primarily at hyperpolarizing potentials. This hypothesis may explain the relatively higher affinity of tertiary amine LAs for the inactivated state (Yeh and Tanguy, 1985). Yeh and Tanguy (1979) further suggested that channel opening
is the rate-limiting step in the dissociation of quaternary LAs from inactivated channels. However, Yeh
and Tanguy (1979) also submit that the rate-limiting step for lidocaine dissociation from inactived channels is deprotonation. Taken together, Yeh and Tanguy’s hypotheses suggest that the charged forms of
tertiary amine LAs dissociate only when channels are open, and inactivation interferes with LA dissociation. However, LAs in their uncharged forms may be able to leave the closed or inactivated channel rapidly through the lipid bilayer. Chernoff and Stricharz (1989) stated that LAs must be charged to demonstrate
phasic blocking capability. The dissociation of uncharged LAs may be as rapid as the rate of recovery
from channel inactivation, which would make phasic blocking undetectable (Chernoff and Strichartz,
1989).
Two major hypotheses attempt to explain the molecular mechanism of phasic block. The guarded
receptor hypothesis states that LA access to receptor(s) on Na channels, but not LA affinity, depends on
channel state (Chernoff and Strichartz, 1989; Starmer, Grant, and Strauss, 1984). Hille’s modulated receptor hypothesis (1977), however, claims that LA receptor binding affinity, but not access, depends on
channel state. This hypothesis is based on the fact that tonic and phasic blocking potencies of QX-314
are enhanced while Na channels are open (Chernoff and Strichartz, 1989). Both hypotheses assume that,
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once a LA binds, the Na channel becomes non-conducting until the LA dissociates. The potency of LAs in
blocking Na channels depends on a number of physico-chemical properties.

Bupivacaine Displays Cardiotoxicity in Humans

It has been suggested that ropivacaine, (S)-1-propyl-N-(2,6-dimethylphenyl)piperidine-2carboxamide, is less cardiotoxic than bupivacaine, (RS)-1-butyl-N-(2,6-dimethylphenyl) piperidine-2carboxamide (Bader et al., 1989). Bupivacaine, but not ropivacaine, includes an n-alkyl substitution on the
piperidine ring, which was previously found to enhance its potency and toxicity (af Ekenstam et al., 1957).
All other test agents in the current study lack n-alkyl substituents, which may make them less cardiotoxic
than bupivacaine. Because potency and toxicity correlate fairly well for bupivacaine and its analogs (af
Ekenstam et al., 1957), cardiotoxicity may be predicted from potency; bupivacaine is more potent than
ropivacaine (Bader et al., 1989; Bariskaner et al., 2007).
The presence of n-alkyl substituents on the piperidine nitrogen of lidocaine and its analogs also
correlate with potency. Bokesch, Post, and Strichartz (1986) showed that the CAP blocking potency of
lidocaine homologs with alkyl group substitutions on the tertiary amine nitrogen, increased with the chain
length of the substituents, decreased with the length between the nitrogen atoms, and increased with partition coefficient.
Bupivacaine binds to inactivated Na channels and slowly dissociates from the channels during
hyperpolarization, despite the fact bupivacaine preferentially binds open channels (Courtney, Kendig, and
Cohen, 1978); these effects likely increase bupivacaine’s cardiotoxicity. Cardiac Na channels spend a
relatively large fraction of time in the inactivated state and may display structural motifs that cause LAs to
block them more than skeletal muscle Na channels. Nuss, Tomaselli, and Marbán (1995) found that the
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cardiac Na channels exhibited larger tonic and phasic blocks by lidocaine than skeletal muscle channels.
Bupivacaine blocked Na currents better than lidocaine (Clarkson and Hondeghem, 1985) and showed
phasic blocking action consistent with an affinity for inactivated states.
Karoly et al. (2010) suggested that the Na channel blocking potency of an agent depends on its
preference for binding inactivated states. Anticonvulsant drugs like lacosamide (Errington et al., 2008)
and phenytoin (Lenkowski et al., 2007) act to block Na channels and preferentially bind inactivated channel states. In summary, bupivacaine has an n-alkyl substitution on its piperidine ring that appears to
cause it to bind to the inactivated state of the Na channel in such a way that it enhances its cardiotoxicity.

Physico-Chemical Properties of LAs

Molecular charge is an important determinant of LA potency (Chernoff and Stricharz, 1990; Muroi
and Chanda, 2009). The charged lidocaine derivatives QX-314 and QX-222 have higher potencies when
applied intracellularly versus extracellularly, which suggests that LAs must penetrate the lipid bilayer to
access LA receptors (Chernoff and Stricharz, 1990; Stricharz, 1977; Sholz, 2002). Hydrophilic quaternary
LAs phasically inhibit Na channels by accessing receptors in open channel states intracellularly via what
is called the hydrophilic pathway (Strichartz, 1977). Tertiary amine and quaternary LAs bind significantly
during repetitive depolarization, during which there is more access to LA receptor(s) via the hydrophilic
pathway (Hille, 1977). The uncharged forms of tertiary amine LAs and more lipid-soluble LAs, however,
may directly access LA receptor(s) through the lipid bilayer via the hydrophobic pathway (Hille, 1977).
Because they can rapidly dissociate and escape via the hydrophobic pathway, uncharged LAs likely produce considerably smaller degrees, or undetectable degrees, of phasic block than their charged congeners. The onset of and recovery from block by tertiary amine LAs is more rapid at alkaline extracellular pH
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(Hille, 1977; Lee, Sunami, and Fozzard, 2001). Alkaline extracellular pH further facilitates LA membrane
diffusion (Hille, 1977) and increases LA binding to activated channels (Chernoff and Stricharz, 1990).
The onset rate of channel block and potency are determined to some degree by LA hydrophobicity and size (Muroi and Chanda, 2009; Shandler, 1965). Langerman, Bansinath, and Grant (1994)
showed that the concentration of a number of LAs, including bupivacaine and lidocaine, to block half the
height of APs correlated with partition coefficients. For a number of 2,6-dimethylcarboxamide derivatives
with similar pKa’s, including bupivacaine, lidocaine, and glycylxylidide, tonic blocking potency increased
with the partition coefficient of the uncharged species (Chernoff and Strichartz, 1990). Hydrophobic LAs
are generally more potent tonic blockers and have larger onset rates (Chernoff and Strichartz, 1990). LAs
with alkyl group substitutions on the amino nitrogen and aromatic ring, as bupivacaine has, tend to have
greater hydrophobicities and may lead one to predict bupivacaine to have a large onset rate. Nevertheless, considerably large hydrophobicities, as seen with bupivacaine, produce slower onset rates than expected (Norton, 2008). Bupivacaine’s relatively large size and hydrophobicity most likely slows its diffusion through lipid bilayers and its partitioning into adventitia, perineuria, etc., before reaching Na channel
receptor(s). Large partition coefficients, which correlate with relatively large hydrophobicities, prolong duration of action, as is the case with bupivacaine (Muroi and Chanda, 2009). LA potency most likely can be
better predicted from a combination of determinants like pKa and partition coefficient, as LAs with comparable partition coefficients can show potency increases or decreases with pKa (Chernoff and Strichartz,
1990).
Substitutions on the aromatic ring also influence LA potency. Haeseler et al. (2002) showed that
2,6-dimethylphenol, which shares the substituted aromatic ring moieties of bupivacaine and lidocaine,
blocked Na channels better than lidocaine and the degree of block increased as membrane potential increased; these results show that 2,6-dimethylphenol blocks channels in a similar way as lidocaine does
without having lidocaine’s tertiary amine portion. The type and location of substitutions on the aromatic
ring of a LA may alter its blocking potency.
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Na channels that are modified in their gating kinetics typically produce APs that are altered in size
and shape. Such modification, particularly the delaying of channel inactivation, has been previously
shown to produce paramyotonia and hyperkalemic periodic paralysis (Cannon, 1996; Cannon and Corey,
1993). The interaction between LAs and molecules called activators, which affect channel inactivation,
has yielded insight into the nature and location of the LA receptor(s). The following section provides an
overview of LA-activator interactions.

Activators

Activators like batrachotoxin (BTX) and vertatridine allow Na channels to open at potentials at
which channels ordinarily would be non-conducting and significantly reduce the probability of inactivation,
which causes channels to produce additional currents. Some activators reduce single-channel conductance and bind channels with greater affinity as depolarization frequency increases. While some activators
selectively bind inactivated Na channel states (Willow and Catterall, 1982), activators such as BTX and
veratridine bind open states to induce a persistent Na current. Veratridine, for example, binds open states
and consequently depolarizes the membrane in a manner similarly observed in the rise of an AP (Wang
et al., 2006). Veratridine appears to bind at a site inside the Na channel pore near LA receptor(s) (Son,
Wong, and Strichartz, 2004; Wang et al., 2006) that involves all S6 segments. Scorpion α-toxin activators
typically inhibit inactivation so that Na currents are prolonged but do not alter the voltage dependence of
their opening and closing.
Scorpion α-toxins, such as those from Buthus martensii Karsch (BmK), interact with Na channels
(Possani et al., 1999; Tan et al., 2001). Scorpion α-toxins are approximately 60-70 residue-long peptides
that possess a conserved core typically consisting of an α-helix and three antiparallel beta strands. Scor-
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pion α-toxins inhibit fast inactivation, resulting in channels that can activate at lower membrane potentials,
repetitively open, and produce APs with prolonged downstrokes (Possani et al., 1999). These toxins have
been shown to prevent the outward movement of D4S4 during activation (Campos et al., 2008; Catterall et
al., 2007). Two α-toxins from the scorpions Leiurus quinquestriatus, LqIIa, and Centruroides sculpturatus,
CsIVa, were shown to dissociate from channels and restore inactivation after a set of repetitive depolarizations was applied to the channels (Stricharz and Wang, 1986). These results suggest that toxin binding
is voltage dependent. In addition, LAs tend to block scorpion α-toxin-bound Na channels preferentially.
For instance, Khodorova et al. (2001) found that lidocaine rapidly blocked repetitively firing compound
APs produced by channels activated by toxins from anemone or scorpion.
LAs competitively and allosterically inhibit some activators (Wang et al., 2006; Willow and Catterall, 1982; Willow et al., 1986). Higher concentrations of veratridine are required to depolarize membranes
pretreated with lidocaine, which may imply competitive inhibition between LAs and activators similar to
veratridine (Wang et al., 2006). The potency of LAs to block BTX-treated Na channels is reduced, suggesting LAs dissociate BTX from Na channels initially activated by BTX (French, Zamponi, and Sierralta,
1998; Willow et al., 1986; Wang and Wang, 1992). LAs have previously been used therapeutically for
myotonia and pain syndromes (Chabal, Russell, and Burchiel, 1989), conditions that involve the delaying
and/or elimination of Na channel inactivation and that are mimicked by the action of some activators.

Objectives and Major Conclusions

Bupivacaine’s action, particularly its toxicity, is due to its chemical structure. Local anesthetics,
especially bupivacaine, possess the risk for malignant arrhythmia, hypotension, conduction delay, and
cardiovascular collapse (Morrison et al., 2000). Although ropivacaine and levobupivacaine, more recent
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bupivacaine congeners, have been shown to have lower risks of serious cardiotoxicity than bupivacaine,
they are not as potent or as long-lasting as bupivacaine (Morrison et al., 2000). The CPs represent a
class of LAs that have not been previously studied since the 1957 synthesis of bupivacaine-like LAs. It
remains to be shown how bupivacaine’s chemical structure determines its anesthetic action. The CPs
studied vary mainly in their substituted aromatic rings, which play significant roles in interactions with Na
channels; therefore, differences in their action provide clues to how changes in the ring structure alters
Na channel block. This knowledge would yield much needed insight into the development of better LAs
and other drugs that act on Na channels. Some CPs are uncharged at physiologic pH, which will likely
make them effective in causing AP block in inflamed regions of the body. The CPs do not have a n-alkyl
substituent on the piperidine ring, which was previously reported to increase the cardiotoxicity of bupivacaine (af Ekenstam et al., 1957).
To test the claim that changes in the number and position of substituents on the aromatic ring of
the CPs alter anesthetic potency and properties, a number of CPs were evaluated for their tonic block,
phasic block, and α-scorpion toxin-modified block of APs. Both CPs in which the carbonyl carbon is directly bonded to the piperidine nitrogen (the 1Ns) and to the carbon adjacent to the nitrogen on the piperidine ring (the 2Ns) were investigated. To determine if potency trends obtained from frog experiments apply to mammalian nerve, select CPs were evaluated for tonic block of APs in rat nerve.
There were several important findings in this study. Bupivacaine’s structural platform, which includes the α-amide linkage, piperidine ring, and 2,6-dimethyl arrangement, is significant for AP block.
While bupivacaine was the most potent blocker, the other CPs blocked APs in a similar manner, suggesting that the CPs have clinical potential. The CPs with two methyl substituents, or the 1NXXCPs, were
generally less potent than the CPs with one methyl substituent, the 1NXCPs. The CPs that featured bupivacaine’s α-amide linkage, the 2Ns, were the most potent group of all CPs. Blocking potency depended
on the number and position of methyl substituents on the aromatic ring. Potency was maximized when
the methyl groups were separated by two positions. The dose-response curves for the tonic block by the
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CPs represented a range of slopes.and may suggest CPs interact with Na channels at more than one
site.
This work investigated the relative reversibility, affinity for the open Na channel state, phasic
blocking capacity, and potency in rat nerve of the CPs. Based on the degree of recovery from AP block of
the CPs, the CPs may present fewer adverse effects than bupivacaine. Bupivacaine and the other 2NCPs as a group had the lowest recoveries, which suggests that the α-amide structure is related to bupivacaine’s toxicity, as af Ekenstam et al. (1957) previously determined. Lidocaine, 1N34CP, and 1N35CP
showed. an increased affinity for open channel states than for closed states but bupivacaine and all other
CPs did not. Virtually all CPs demonstrated phasic blocking capacity. This suggests that molecular
charge is not essential for phasic block. All CPs evaluated in rat nerve had the same tonic blocking potency in frog nerve and suggests that potency trends from frog experiments may apply to human nerves.

CHAPTER 2
METHODOLOGY

Nerve Preparation

Compound APs (CAPs) were recorded from desheathed frog (Rana pipiens) sciatic nerve using
the single sucrose gap technique (Hahin and Kondratiev, 2001) (see Figure 4). Adult grass frogs (Charles
D. Sullivan Co. Inc., Nashville, Tennessee) were euthanized by rapid decapitation, in accordance with
procedures approved by the Institutional Animal Care and Use Committee (IACUC). Sciatic nerves were
dissected from the lumbar plexus to the tibial and peroneal branches just distal to the knee. If not immediately used, nerves were stored in Ringer’s solution at 4°C for no longer than 3 days. The nerves were
desheathed and mounted in the chamber with the proximal end in the intracellular pool, containing buffered isosmotic KCl. The body of the nerve passed through the gap partition, which was continually perfused with isosmotic sucrose at a rate of 6 mL/min. The distal end of the nerve was in the extracellular
pool and contained Ringer’s solution with or without test substances and was electrically grounded. The
intracellular and extacellular pools were electrically isolated via petrolatum seals around the nerve and
sucrose flow to create a resistance greater than 1 MΩ. Both KCl and Ringer’s solution were replaced every 30 minutes to maintain solution levels in the compartments. The extracellular end of the nerve was
placed in to an external cylindrical glass suction electrode via an applied vacuum. The suction electrode
contained a Ag-AgCl electrode, Ringer’s solution and paraffin oil and was electrically connected to the
recording apparatus via shielded cable. CAPs were differentially recorded in the intracellular pool relative
to the extracellular pool using a digitial oscilloscope (Tektronix TDS 340A, Beaverton, OR). CAPs were
filtered using a 40 kHz filter and stored on diskettes for later analysis. Experiments were conducted at
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room temperature only with nerves that initially had a stable CAP of at least 50 mV over a 30-min period
and if the CAP shape did not vary with the sucrose flow rate.
𝑉
stimulation
to oscilloscope

saline compartment
KCl compartment

nerve

direction of sucrose flow

Figure 4. Sucrose-gap technique setup. is the potential in the KCl chamber, relative to the extracellular
pool. Depolarizing stimuli were applied to the nerve end in the extracellular pool.

Solutions

Ringer’s solution (frog nerve) contained 112 mM NaCl, 2 mM CaCl 2, 2 mM KCl, and 10 mM 4-(2hydroxyethyl)-1-piperazineethane-sulfonic acid (HEPES) and was adjusted to pH 7.40 using 10 N NaOH.
Krebs solution (rat nerve) contained 135 mM NaCl, 1.8 mM CaCl 2, 5.4 mM KCl, and 2.4 mM NaHCO3 and

19
was adjusted to pH 7.40 using 2 N NaOH. Extracellular solutions were used for storing nerves, in the extracellular pool, and for producing dilutions of test agents. The intracellular solution contained 112 mM
KCl and 20 mM HEPES, adjusted to pH 7.40 with 10 N KOH. This isotonic KCl solution counteracts the
hyperpolarization produced by the sucrose flow and the junction potential between extracellular solution
and sucrose (Blaustein and Goldman, 1966). The 0.18 M sucrose solution minimized extracellular shunting during CAP propagation.

Stimulation and Recording

Square wave 0.15 ms-long pulses were applied to the nerve by a Grass S48 stimulator at various
frequencies, depending on the type of experiment. CAPs were collected at a sampling frequency of 100
MS/sec using a data acquisition system (Measurement Computing USB-1208FS, Norton, MA) and subsequently analyzed using Microsoft Excel. Baseline CAP height and duration were recorded after the
CAP height stabilized before adding test agents to the extracellular pool.
In tonic block experiments, recordings were taken every five minutes and six consecutive steady
CAPs were obtained prior to test solute addition to represent baseline height. Stimuli were applied at 0.5
pulses per second (pps). In experiments where nerves were treated with α-toxin prior to test solute addition, recordings were taken every five minutes and four consecutive control CAPs were obtained prior to
α-toxin addition. Stimuli were applied at 0.2 pps. α-toxin was removed when CAP duration was at least 50
ms, and test solute was immediately added in Ringer’s solution after α-toxin was removed. In phasic
block experiments, a 1-second train of pulses at either 10 pps or 20 pps was applied and the degree of
attenuation of CAP block between the first and last pulses was used to evaluate phasic block capability
relative to bupivacaine.
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CPs

The original set of CPs, shown in Table 1, were purchased from Sigma Chemicals (St. Louis,
Missouri); bupivacaine and lidocaine were purchased from Abbott Laboratories. CP solutions were prepared using a volume per volume dilution in extracellular Ringer’s or Krebs solution and were adjusted to
pH 7.40. ChemSketch was used to estimate the octanol-water partition coefficient and SPARC (Sparc
Performs Automated Reasoning in Chemistry) was used to estimate pKa.

Table 1
Structures of the Original CPs.

R4
O
N
R6

R5

R3

NH

R2
R1

identifier
1N2CP
1-(N-(o-tolyl)carbamoyl)piperidine
1N3CP
1-(N-(m-tolyl)carbamoyl)piperidine
1N4CP
1-(N-(p-tolyl)carbamoyl)piperidine
1N25CP
1-(N-(2,5-xylyl)carbamoyl)piperidine
1N34CP
1-(N-(3,4-xylyl)carbamoyl)piperidine
1N35CP
1-(N-(3,5-xylyl)carbamoyl)piperidine
1N26CP
1-(N-(2,6-xylyl)carbamoyl)piperidine
4mNmTPCP
4-methyl-1-(N-(4-methylthio)phenyl)carbamoyl)piperidine
*unmentioned substituents are hydrogens

substituents*
R1 = CH3
R2 = CH3
R3 = CH3
R1 = CH3, R4 = CH3
R2 = CH3, R3 = CH3
R2 = CH3, R4 = CH3
R1 = CH3, R5 = CH3
R3 = SCH3, R6 = CH3
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α-Toxin

Buthus martensii Karsch (BmK) 16(5) α-toxin, previously isolated and purified by Hahin, Chen
and Reddy (2000), was used to lengthen the duration of CAPs by direct application to Ringer’s solution
bathing the nerve and be referred to as α-toxin Ringer’s solution.

Potency and Recovery Calculations

CAP recordings were obtained using the following procedure. CAPs were recorded in Ringer’s (or
in α-toxin Ringer’s) control solution followed by a test solution containing a CP in Ringer’s solution and
finally in Ringer’s solution. To remove the test solute solution, three washouts with Ringer’s solution was
used. CAP recordings were used to obtain the time course and degree of AP block in the test solution.
The relative CAP height or duration defined by steady state height or duration values due to test solute,
referred to as response, was measured. After the test solute solution was replaced with Ringer’s solution,
elicited CAPs grew in height until the heights achieved some steady state value, defined to be the CAP
height that remains unchanged for 30 minutes. Reversibility of block, referred to as recovery, was estimated by the steady-state CAP height in Ringer’s solution (after the test solute was removed) divided by
the corresponding CAP height in Ringer’s solution prior to the addition of test solute. Dose-response and
dose-recovery relations were fit by the logistic equations (1)-(4). The dose-response curve for CAP height
block has the form
( )

[

(

) ]

(1)
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( ) is CAP height relative to baseline height at concentration

where

blocking concentration (in mM), and

(in mM),

is half-height

is the slope parameter. The dose-response curve for CAP dura-

tion block has the form
( )

[

(

) ]

(2)

( ) is CAP duration relative to baseline duration at concentration

where

duration blocking concentration (in mM), and

(in mM),

is the half-

is the slope parameter. The dose-recovery curve for CAP

height block has the form
( )

[

(

) ]

( ) is CAP height recovery relative to baseline height at concentration

where

concentration (in mM) at which relative recovery is

, and

(3)

(in mM),

is the

is the slope parameter. Finally, the dose-

recovery curve for CAP duration block has the form
( )

[

(

) ]

( ) is CAP duration recovery relative to baseline duration at concentration

where

the concentration (in mM) at which relative recovery is

, and

(4)

(in mM),

is the slope parameter. The Leven-

berg–Marquardt algorithm was used to obtain least-squares estimates of the parameters
,

,

,

,

, and

is

,

,

for each CP. Blocking potency was defined as the reciprocal of ED50.

An F-test assessed the significance of (1)-(4).
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Syntheses

Figure 5 shows the general reaction scheme for the synthesized CPs. Table 2 shows the final
synthetic products. 1-BOC-piperidine-2-carboxylic acid (1, 1 mmol, 1 eq), the appropriate substituted aniline (2, 1 mmol, 1 eq), and HOBt (3, hydroxybenzotriazole, 1 mmol, 1 eq) in anhydrous CH2Cl2 (50
mL) was stirred at 0°C under inert atmosphere (N2). A solution of EDC HCl salt (4, 1-ethyl-3-(3dimethylaminopropyl)carbodiimide hydrochloride, 1 mmol, 1 eq) with Et3N (5,1 mmol, 1 eq) in anhydrous
CH2Cl2 (10 mL) was added dropwise under inert atmosphere at reduced temperature. The resulting solution was allowed to warm to room temperature following complete addition of the EDC solution. After 24
h, the solution was poured over EtOAc (100 mL) and the organic layer was washed with water (2 x 50
mL), washed with brine (2 x 50 mL), and dried over anhydrous sodium sulfate. The reaction solvent was
removed in vacuo, yielding crude product as a yellow solid. HCl was used to deprotect the product. Purification was carried out via flash chromatography on silica gel utilizing a hexane:EtOAc gradient (0%
EtOAc to 50% EtOAc). Fractions were analyzed by TLC (30% EtOAc:hexane) and product fractions were
collected and concentrated, yielding 6a-c (see Table 2) as a white solid. Reaction progress was monitored using analytical thin-layer chromatography on pre-coated silica gel plates and the spots were detected under 254 nm. All reagents and solvents were purchased from Sigma-Aldrich and used without
further purification.

4

1

2

3

5

0°C, 2 h
rt, 24 h

6a-c

Figure 5. General scheme of syntheses. Reactions were performed under anhydrous conditions.
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Table 2
Synthesized CPs.

Identifier
6a. 2NCP
N-(phenyl)piperidine-2-carboxamide
6b. 2N24CP
N-(2,4-dimethylphenyl)piperidine-2-carboxamide
6c. 2N246CP
N-(2,4,6-trimethylphenyl)piperidine-2-carboxamide
*unmentioned R groups are hydrogen atoms

CH3 substituents*
none
R1, R3
R1, R3, R5

1

H NMR were recorded in deuterated chloroform at 300MHz on a Bruker NMR spectrometer.

Chemical shifts are expressed in ppm.
2NCP:

1

H NMR (500 MHz, CDCl3, ppm): 1.46-1.64 (4H, m, CH2), 1.75 (1H, s, NH), 1.83-1.85 (1H, m,

CH2), 2.05 (1H, dd, CH2), 2.78 (1H, dt, CH2), 3.08 (1H, dt, CH2), 3.36 (1H, dd, CH), 7.11 (1H,
t, Ar), 7.34 (2H, t, Ar), 7.59 (2H, d, Ar), 8.87 (1H, s, NH)
2N24CP:

1

H NMR (500 MHz, CDCl3, ppm): 1.50 (2H, d, CH2), 1.63 (3H, s, CH2), 1.84 (1H, s, NH), 2.07

(1H, s, CH2), 2.26 (3H, s, CH3), 2.30 (4H, s, CH3), 2.81 (1H, s, CH2), 3.11-3.13 (1H, m, CH2),
3.48 (1H, dd, CH) , 7.01 (2H, s, Ar), 7.78 (1H, d, Ar), 8.84 (1H, s, NH)
2N246CP:

1

H NMR (500 MHz, CDCl3, ppm): 1.25 (1H, s, NH), 1.50-1.60 (2H, m, CH2), 1.70 (2H, t, CH2),

1.71-1.87 (2H, m, CH2), 2.12 (2H, dd, CH2), 2.20 (6H, s, CH3), 2.28 (3H, s, CH3), 2.83-2.88
(1H, m, CH), 3.17 (1H, d, CH), 3.56 (1H, t, CH), 6.90 (2H, s, Ar), 8.31 (1H, s, NH)

CHAPTER 3
RESULTS

CP Tonic Block

CPs blocked CAP heights in a concentration-dependent manner. Figures 6-11 show the typical
protocol used to obtain dose-response data for tonic block experiments for each test agent. The dose
used, percent block (blk), and percent recovery (rec) are given for three doses for the shown to the right
of each panel (A, B or C). After the CAP height stabilized for a 30-minute period, the Ringer’s solution
was replaced (indicated by C in each figure) by a test agent in Ringer’s solution. The time course of CAP
block was obtained by eliciting CAPs until a steady-state block occurred. After steady-state block was
observed, the test agent solution was replaced by Ringer’s solution (indicated by R in each figure). CAPs
were elicited every 2 sec throughout the experiment. If recovery was at least 90% of the control CAP
height and the post-test solute CAP remained unchanged in height for 30 minutes, a second dose of the
same test agent was applied to the same nerve to reduce the variation caused by using different nerves.
In experiments where more than one dose of the same test agent was applied to the same nerve, the order of the doses evaluated was randomized. As concentration increased, CAP block increased. CAPs
were recorded every 5 minutes and are shifted by 5 ms to the right of the immediately previous CAP.
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Figure 6. Tonic block of CAPs at three doses of bupivacaine.
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Figure 7. Tonic block of CAPs at three doses of lidocaine.
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Figure 8. Tonic block of CAPs at three doses of 1N25CP.
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Figure 9. Tonic block of CAPs at three doses of 1N3CP.
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Figure 10. Tonic block of CAPs at three doses of 4mNmTPCP.
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Figure 11. Tonic block of CAPs at three doses of 2N24CP.
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Tonic Block Relations

Figures 12-14 show the tonic block dose-response relations for all CPs. To produce doseresponse relations, results for five different doses with at least three replicates per dose were obtained for
each solute. Each figure contains standard error bars. Figure 12 and 13, respectively, show doseresponse relations for CPs that feature the 1N- structure and have two methyl group substituents on the
aromatic ring (1NXXCPs) or one methyl group substituent (1NXCPs). Figure 14 shows dose-response
relations for the 2N- CPs. Dose-response relations for all test agents, except for bupivacaine and lidocaine, are represented by unfilled symbols.
All curve fits had

< 0.01. Figures 12-14 show that the dose-response curves for the test agents

exhibit a wide range of slopes and generally cannot coincide with other curves simply through horizontal
shifts. However, the curves for bupivacaine and 2N246CP ( ) are very similar in shape.

Figure 12. Dose-response curves for bupivacaine and 1NXXCPs. Bupivacaine (♦), lidocaine (■), 1N25CP
(□), 1N34CP (○), 1N35CP ( ), and 1N26CP ( ). Dashed lines indicate the curves fit for bupivacaine or
lidocaine.
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Figure 13. Dose-response curves for bupivacaine and 1NXCPs. Bupivacaine (♦), lidocaine (■), 1N2CP
(□), 1N3CP (○), and 1N4CP ( ).

Figure 14. Dose-response curves for bupivacaine and 2N- CPs. Bupivacaine (♦), lidocaine (■), 2NCP (□),
2N24CP (○), and 2N246CP ( ).

Figures 15 and 16 represent tonic block dose-recovery curves for the 1NXXCPs and 1NXCPs,
respectively. Each figure contains standard error bars. Dose-recovery curves for bupivacaine and lidocaine are displayed in each figure for comparison purposes. All curve fits had
(

= 0.0162) and 1N4CP (

< 0.01, except for 1N3CP

= 0.0146). The recovery relationships illustrate that recovery was dose-
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dependent. The shapes of the recovery relations varied considerably, showing that the degree of recov-

Relative CAP Recovery (%)

ery was dependent on CP structure.

Relative CAP Recovery (%)

Figure 15. Dose-recovery curves for bupivacaine and 1NXXCPs. Tonic block dose-recovery curves for
bupivacaine (♦), lidocaine (■), 1N25CP (□), 1N34CP (○), 1N35CP ( ), and 1N26CP ( ).

Figure 16. Dose-recovery curves for bupivacaine and 1NXCPs. Tonic block dose-recovery curves for bupivacaine (♦), lidocaine (■), 1N2CP (□), 1N3CP (○), and 1N4CP ( ).

Table 3 shows tonic block dose-response and dose-recovery curve parameters and chemical
properties for all test agents. Bupivacaine, lidocaine, and the other CPs tested are shown in the first column and subsequent columns show the molar volume, the log of the octanol-water partition coefficient,
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the acid dissociation constant (expressed as –
,

,

, and

), and the block and recovery parameters (i.e.,

) obtained from curve fits to dose-response and dose-recovery relations. Using

the dose-recovery relationships, an estimate for the expected amount of recovery,
dose was obtained and is shown as the last column entry in the table:

(

, at the
).

Table 3
Test Agent Chemical Properties and Tonic Block Parameters.
vol = molar volume in mL; log P = log octanol-water partition coefficient;
in mM;
= slope parameter;
in mM;
is the test agent potency relative to bupivacaine;
is the estimated relative re(
)). ± indicates standard error.
covery at the ED50 concentration (
chemical properties

tonic block parameters

vol

log P

pKa

bupivacaine

279.48

3.64

8.07

0.83±0.05

2.43±0.30

1.22±0.09

1

0.684

lidocaine

228.40

2.36

8.18

4.73±0.30

2.33±0.16

6.89±0.31

0.175

0.705

1N35CP

208.73

2.83

0.39

3.34±0.07

4.20±0.39

4.20±0.30

0.249

0.744

1N26CP

208.73

2.83

0.39

3.94±0.06

3.73±0.15

6.19±0.58

0.211

0.843

1N25CP

208.73

2.83

0.35

7.85±0.40

1.58±0.15

10.5±0.52

0.106

0.651

1N34CP

208.73

2.83

0.43

8.63±0.17

1.87±0.08

17.0±0.09

0.096

0.718

1N3CP

192.30

2.37

0.19

1.70±0.01

9.41±0.69

1.98±0.06

0.488

0.748

1N4CP

192.30

2.37

0.22

3.58±0.33

3.62±0.99

5.47±0.63

0.232

0.749

1N2CP

192.30

2.37

0.14

8.73±0.08

4.08±0.17

12.0±0.42

0.095

0.752

2N246CP

246.35

2.75

8.94

1.06±0.03

2.80±0.26

1.67±0.14

0.783

0.726

2N24CP

232.32

2.29

8.73

2.38±0.18

2.92±0.75

3.21±0.15

0.349

0.662

2NCP

204.27

1.37

8.44

4.42±0.21

4.11±0.85

5.57±0.24

0.188

0.672

4mNmTPCP

228.50

2.79

-0.01

4.02±0.12

9.05±2.4

5.85±0.03

0.206

0.926
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α-Toxin-Treated CAP Block

To determine whether CPs block open Na channels over their closed counterparts (preferably
block open channels), nerves were treated with a scorpion α-toxin (BmK 16(5)) that abolishes fast inactivation and causes Na channels to open and close repeatedly and thus occupy the open state for a relatively longer period of time. Nerves treated with BmK 16(5) exhibit CAPs that become increasingly prolonged the longer nerve fibers are exposed to the toxin. The CAPs develop a long “tail” and decrease
slightly in height in the presence of the toxin. The tail develops as Na channels lose their ability to inactivate when in the presence of the toxin. Bupivacaine, lidocaine, the 1NXXCPs, and the 1NXCPs were
tested for their ability to block the heights and durations of toxin-altered CAPs. If CPs preferably block
open channels, then the CAP tail (duration) should be blocked to a greater extent than the CAP height.
The heights and durations of toxin-altered CAPs were reduced in a concentration-dependent manner.
Figures 17-21 show examples of α-toxin-treated CAP block experiments for bupivacaine, lidocaine, 1N25CP, 1N3CP, and 4mNmTPCP at three different concentrations for each test substance. Each
of the other CPs were tested in a similar fashion, but are not shown. Each figure represents the CAP
height (ordinate) versus time (abscissa). CAPs were stimulated frequently (see methods); however, CAPs
are shown every 5 minutes and each CAP is shifted rightward by 5 msec to represent the progression of
time. In each figure, the first 4 CAPs represent the baseline CAP height and duration during a 20-minute
period prior to the addition of the BmK 16(5) toxin to the nerve. At the CAP labeled by a T, the toxin was
applied to the extracellular solution bathing the nerve. The toxin lengthened the CAP in time; each successively stimulated CAP exhibited a longer “tail.” After the CAP had lengthened to exactly 50 ms, the
toxin solution was immediately replaced with Ringer’s solution containing a test agent (indicated by C). A
set of successive CAPs was elicited until the CAP height reached a new steady-state value. After reaching this steady-state height, the test agent solution was replaced with Ringer’s (indicated by an R) in order
to wash off the test agent from the bath and observe the time course of recovery. In each figure, below
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the concentration of the test agent are symbols that designate, in percent, the block of the height (hblk),
the recovery of the height (hrec), the block of duration (tblk), and the recovery of the duration (trec).
Figures 22-25 show the α-toxin-treated nerve dose-response and dose-recovery relationships for
CAP height. Figure 22 shows α-toxin-treated nerve dose-response curves for CAP height for bupivacaine
and the 1NXXCPs. Figure 23 shows α-toxin-treated nerve dose-response curves for CAP height for bupivacaine and the 1NXCPs. In each figure, dashed traces indicate the logistic model curve fits for bupivacaine or lidocaine. All bars represent standard error. For all fits,

< 0.01. Figure 24 shows α-toxin-treated

nerve dose-recovery curves for CAP height for bupivacaine and the 1NXXCPs. Figure 25 shows α-toxintreated nerve dose-recovery curves for CAP height for bupivacaine and the 1NXCPs. For all fits,

< 0.01,

except for 1N3CP ( = 0.0162) and 1N4CP ( = 0.0146).
After α-toxin treatment of nerves, CAPs were prolonged and the addition of test agents to the
nerve shortened the duration of the CAPs. Figures 26-29 show the α-toxin-treated nerve dose-response
and dose-recovery relationships for CAP duration. Figure 26 shows α-toxin-treated nerve dose-response
curves for CAP duration for bupivacaine and the 1NXXCPs. Figure 27 shows α-toxin-treated nerve doseresponse curves for CAP duration for bupivacaine and the 1NXCPs. For all fits,

< 0.01.

After removal of the test agents, the CAPs recovered to a more prolonged state, depending on
the concentration of the test agent. After recovery reached a steady-state value, the fractional degree of
recovery was plotted as a function of the concentration of the test agent applied to the nerve. Figure 28
shows α-toxin-treated nerve dose-recovery curves for CAP duration for bupivacaine and the 1NXXCPs.
Figure 29 shows α-toxin-treated nerve dose-recovery curves for CAP duration for bupivacaine and the
1NXCPs. For all fits,

< 0.01.

Table 4 shows α-toxin-treated nerve dose-block and dose-recovery parameters for the block of
CAP height. Table 5 shows α-toxin-treated nerve dose-block and dose-recovery parameters for the block
of CAP duration. Slope parameters vary considerably and do not depend on number of methyl groups.
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Figure 17. Block of toxin-treated nerves for bupivacaine.
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Figure 18. Block of toxin-treated nerves for lidocaine.

Figure. Toxin block experiments at A. 1.00 mM, B. 3.00 mM, and C.
5.00 mM lidocaine. T = addition of toxin BmK 16(5) after CAP record-
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Figure 19. Block of toxin-treated nerves for 1N25CP.

Figure. Toxin block experiments at A. 1.00 mM, B. 3.00 mM, and C.
5.00 mM lidocaine. T = addition of toxin BmK 16(5) after CAP record-
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Figure 20. Block of toxin-treated nerves for 1N3CP.

Figure. Toxin block experiments at A. 1.00 mM, B. 3.00 mM, and C.
5.00 mM lidocaine. T = addition of toxin BmK 16(5) after CAP record-
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Figure 21. Block of toxin-treated nerves for 4mNmTPTP.
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Figure. Toxin block experiments at A. 1.00 mM, B. 3.00 mM, and C.
5.00 mM lidocaine. T = addition of toxin BmK 16(5) after CAP record-
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Figure 22. α-toxin-treated nerve dose-response curves for height for 1NXXCPs. α-toxin-treated nerve
dose-response relations for CAP height for bupivacaine (♦), lidocaine (■), 1N25CP (□), 1N34CP (○),
1N35CP ( ), and 1N26CP ( ).

Figure 23. α-toxin-treated nerve dose-response curves for height for 1NXCPs. α-toxin-treated nerve doseresponse relations for CAP height for bupivacaine (♦), lidocaine (■), 1N2CP (□), 1N3CP (○), and 1N4CP
( ).

Relative CAP Recovery (%)
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Figure 24. α-toxin-treated nerve dose-recovery curves for height for 1NXXCPs. α-toxin-treated nerve
dose-response relations for CAP height for bupivacaine (♦), lidocaine (■), 1N25CP (□), 1N34CP (○),
1N35CP ( ), and 1N26CP ( ).

Figure 25. α-toxin-treated nerve dose-recovery curves for height for 1NXCPs. α-toxin-treated nerve doseresponse relations for CAP height for bupivacaine (♦), lidocaine (■), 1N2CP (□), 1N3CP (○), and 1N4CP
( ).
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Figure 26. α-toxin-treated nerve dose-response curves for duration for 1NXXCPs. α-toxin-treated nerve
dose-response relations for CAP duration for bupivacaine (♦), lidocaine (■), 1N25CP (□), 1N34CP (○),
1N35CP ( ), and 1N26CP ( ).

Figure 27. α-toxin-treated nerve dose-response curves for duration for 1NXCPs. α-toxin-treated nerve
dose-response relations for CAP duration for bupivacaine (♦), lidocaine (■), 1N2CP (□), 1N3CP (○), and
1N4CP ( ).

Relative CAP Recovery (%)
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Figure 28. α-toxin-treated nerve dose-recovery curves for duration for 1NXXCPs. α-toxin-treated nerve
dose-recovery relations for CAP duration for bupivacaine (♦), lidocaine (■), 1N25CP (□), 1N34CP (○),
1N35CP ( ), and 1N26CP ( ).

Figure 29. α-toxin-treated nerve dose-recovery curves for duration for 1NXCPs. α-toxin-treated nerve
dose-recovery relations for CAP duration for bupivacaine (♦), lidocaine (■), 1N2CP (□), 1N3CP (○), and
1N4CP ( ).
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Table 4
α-Toxin-Treated Nerve CAP Height Block Parameters.

in mM;
= slope parameters;
rameter in mM. ± indicates standard error.

= recovery pa-

CP
bupivacaine

0.75±0.05

2.70±0.40

0.98±0.03

1.73±0.12

lidocaine

3.49±0.51

1.37±0.29

4.07±0.46

1.40±0.25

1N35CP

3.00±0.20

3.24±0.77

3.81±0.18

5.80±01.6

1N26CP

3.88±0.22

2.72±0.35

5.99±0.55

2.32±0.34

1N25CP

5.90±0.19

1.40±0.47

8.32±0.63

1.81±0.27

1N34CP

6.67±0.63

1.58±0.24

17.1±0.89

1.38±0.11

1N3CP

1.63±0.02

11.0±1.5

1.74±0.05

5.45±01.2

1N4CP

3.28±0.14

3.70±0.55

4.66±0.24

1.97±0.20

1N2CP

7.69±0.04

3.64±0.09

8.87±0.72

3.21±0.87

4mNmTPCP

4.01±0.25

6.91±03.2

4.49±0.24

3.40±0.69
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Table 5
α-Toxin-Treated Nerve CAP Duration Block Parameters.

in mM;
= slope parameters;
rameter in mM. ± indicates standard error.

= recovery pa-

CP
bupivacaine

0.73±0.08

1.85±0.36

0.96±0.11

1.66±0.34

lidocaine

1.53±0.15

0.93±0.09

2.42±0.51

0.89±0.20

1N35CP

1.66±0.33

2.83±0.30

10.6±0.96

1.79±0.27

1N26CP

3.64±0.29

1.93±0.31

5.52±0.54

1.83±0.27

1N34CP

4.01±0.46

1.58±0.30

5.26±0.85

1.46±0.34

1N25CP

5.43±01.0

0.87±0.18

11.0±01.5

0.75±0.08

1N3CP

1.63±0.03

9.91±1.7

1.66±0.10

5.29±2.2

1N4CP

3.21±0.17

2.77±0.44

4.01±0.25

2.05±0.27

1N2CP

6.86±0.38

4.35±01.1

7.48±0.34

3.48±0.64

4mNmTPCP

3.46±0.34

2.39±0.56

3.83±0.35

2.24±0.50

Phasic Block

Table 6 shows percent phasic block at 10 pps and 20 pps for all test agents evaluated for phasic
block. Figure 30 show the attenuation of CAP height for 1.50 mM bupivacaine at the stimulation rates of
10 pps (top) and 20 pps (bottom). Tonic block refers to the degree of height block of the CAP in the presence of test agent that occurs prior to stimulation. However, with repetitive stimulation, block progressively increased and the additional phasic block was obtained by comparing the last CAP height compared to
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the pre-stimulation CAP height. Since all differences in CAP heights were less than 1 mV, these differences are difficult to discern in Figure 30. Nevertheless, the difference in heights of successive CAPs was
approximately constant. Similar experiments were performed on all test agents besides bupivacaine and
the 2N- CPs. The CPs were less likely to produce any additional block compared to bupivacaine and lidocaine and this can be seen in Table 6. Table 6 shows that 1N26CP was the most effective CP in inducing
additional block after a 20-pulse repetitive stimulation sequence.

Figure 30. Phasic block by 1.50 mM bupivacaine at 10 pps and 20 pps.
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Table 6
Phasic Block of CAP Height.

Values are in % of block of baseline CAP
height. ± indicate standard error.
CP

10 pps

20 pps

bupivacaine

1.77±0.05

2.58±0.03

lidocaine

1.18±0.04

2.75±0.06

1N26CP

0.98±0.11

1.20±0.08

1N34CP

0.84±0.08

0.90±0.05

1N25CP

0.80±0.09

1.21±0.08

1N35CP

0.55±0.08

0.90±0.06

1N4CP

0.54±0.06

0.69±0.06

1N2CP

0.45±0.03

0.64±0.09

1N3CP

0.27±0.06

0.59±0.05

4mNmTPCP

0.60±0.03

1.15±0.06

Rat Tonic Block

For select CPs, tonic block experiments were repeated in rat sciatic nerve in order to identify any
significant differences in blocking action. Tonic block experiments using rat nerves were conducted (results not shown) in a manner analogous to the experiments performed previously using frog nerves. Experiments were conducted using 1N34CP, 1N3CP, and 4mNmTPCP and bupivacaine as test agents.
Figures 31 and 32 show the rat tonic block dose-block and dose-recovery curves, respectively, of the
aforementioned test agents. All fits had

< 0.01. Rat tonic block dose-response and dose-recovery
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curves for bupivacaine are shown for comparison purposes and indicated as a dotted trace. Table 7 compares the frog tonic block and rat tonic block dose-response and dose-recovery parameters of CAP
height of bupivacaine, 1N34CP, 1N3CP, and 4mNmTPCP. The differences in ED50s between rat and
frog experiments per test agent were not significant.

Relative CAP Recovery (%)

Figure 31. Rat tonic block dose-response curves. Rat tonic block dose-block curves for bupivacaine (♦),
1N34CP (□), 1N3CP (○), and 4mNmTPCP ( ).

Figure 32. Rat tonic block dose-recovery curves. Rat tonic block dose-recovery curves for bupivacaine
(♦), 1N34CP (□), 1N3CP (○), and 4mNmTPCP ( ).
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Table 7
Rat and Frog Tonic Block Parameters for CAP Height.
in mM;

= slope parameters;

in mM. () indicate standard error.

rat tonic block parameters

frog tonic block parameters

CP
bupivacaine

0.75±0.05

2.87±0.15

1.19±0.08

2.21±0.38

0.83±0.05

1.22±0.09

1N34CP

7.85±0.40

2.27±0.86

16.9±1.3

1.53±0.21

8.63±0.17

17.0±0.09

1N3CP

1.66±0.02

7.85±0.29

2.05±0.01

6.23±0.22

1.70±0.01

1.98±0.06

4mNmTPCP

3.47±0.26

8.65±1.7

6.03±0.08

5.15±0.30

4.02±0.12

5.85±0.03

CHAPTER 4
DISCUSSION

Comparison of Results for Lidocaine and Bupivacaine

Previous work showed that bupivacaine is a more potent tonic blocker than lidocaine. Buyukakilli
et al. (2003) exposed frog sciatic nerve to 10 mM, 20 mM, and 30 mM bupivacaine for 20 minutes and
recorded action potential changes. Buyukakilli et al. (2003) obtained an estimate of the ED50 of 62.9
mM, compared to 0.83 mM in this study. Langerman, Bansinath, and Grant (1994) obtained ED50s for
bupivacaine and lidocaine in mice via intrathecal spinal injections and obtained values of 0.42 mM and
4.18. Shown in Table 8 is a comparison of the results of the different estimates of ED50s obtained from
AP block.
Buyukakilli et al. (2003) stimulated nerve tissue before and after exposure to bupivacaine and
their estimate of ED50 was based on only 3 doses of drug. In the current study nerves were frequently
stimulated (0.5/sec) prior to and after the application of the test agents. Buyukakilli et al. (2003) did not
use desheathed nerves and limited the exposure time of bupivacaine to 20 minutes prior to recording the
diminution of the CAP so diffusion limitations likely caused their results to differ from those obtained in
this study.
Yano et al. (2013) characterized how lidocaine phasic block of propagated APs in crayfish giant
axons was enhanced by dimethylsulfoxide (DMSO) in the bathing solution. In experiments without DMSO
added (figure 3A; Yano et al. 2013), Yano et al. (2013) stimulated axons in the presence of 1 mM lidoth

caine at 20 pulses per second, the stimulation rate used in this study, and found that the 20 AP height
was reduced by approximately 3.6% compared to the first AP. All APs Yano et al. (2013) recorded were
obtained via an intracellular microelectrode into one of the giant axons of the nerve bundle. Results from
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this study using the same protocol were consistent with the results of Yano et al. (2013) and showed a
th

st

3.37% reduction in CAP height when the 20 CAP was compared to the 1 one for 1 mM lidocaine.

Table 8.
AP Block ED50 Estimates for Bupivacaine and Lidocaine.

Values in mM, ( ) standard error in, () standard error not given; a. current study; b. Buyukakilli et al., 2003; c. Langerman,
Bansinath, and Grant, 1994
a
b
c
bupivacaine

0.83 (.05)

62.9 (.70)

0.42 ()

lidocaine

4.73 (.30)

--

4.18 ()

Bupivacaine’s Structural Platform Is Significant

Bupivacaine was the most potent tonic blocker; however, all other test agents had potencies within one order of magnitude of bupivacaine’s. Excluding bupivacaine, 1N3CP, 2N246CP, and 2N24CP were
the other most potent tonic blockers. There are patterns in the 1NXXCP relative potencies that suggest
bupivacaine’s structural platform is significant for producing AP block.
1N26CP, which shares bupivacaine’s methyl-group arrangement and piperidine ring, but lacks
the α-amide linkage, was among the most potent CPs. 1N35CP was more potent than 1N26CP, but
1N34CP was more than two times less potent than 1N26CP. This relative potency variation may be explained by the fact that 1N35CP and 1N26CP have similar aromatic ring methyl group placements: both
have bupivacaine’s piperidine ring and have dimethylphenyl groups in which the methyl groups are not
adjacent to each other. 4mNmTPCP, which has a piperidine ring and lacks methyl group substituents,
was as potent as lidocaine. However, lidocaine has bupivacaine’s methyl substituent arrangement, but
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had one of the smallest potencies of the test agents. These observations suggest that the piperidine ring
moiety contributes more to potency than the dimethylphenyl structure.
However, the 2N-CPs, which featured bupivacaine’s α-amide linkage, were the most potent group
of CPs, which suggests the α-amide linkage contributes more to potency than either the piperidine ring or
the dimethylphenyl structure. The addition of methyl substituents to 2NCP increased potency, with three
methyl substituents conferring the greatest potency within this group and among all CPs after bupivacaine.

Multiple Binding Sites for CPs

Equations (1-4) describing CAP block and recovery each employ a slope parameter (

), similar

to the Hill slope, that describes the steepness of the curves. The Hill slope was first used by Hill to model
the binding of oxygen (O2) to hemoglobin (Hb). Hill’s O2-Hb binding model exhibited positive binding cooperativity; O2 binding to hemoglobin increased the probability that an additional O 2 will bind the same
hemoglobin molecule. As the degree of positive cooperativity increases, so does the Hill slope and the
curve of the fraction of bound O2 becomes steeper, i.e., the maximum curve slope increases. The tonic
block dose-response curves showed a range of maximum slopes

, which are akin to Hill slopes.

When applied to dose-response relations, the Hill slope additionally provides a measure of the
range of safely used (therapeutic) doses. Larger slopes, or steeper dose-response curves, imply a narrow
clinical therapeutic range of doses, whereas smaller slopes, as seen in the case of 1N25CP, 1N34CP,
and 1N2CP, suggest that these drugs would block Na channels in varying degrees over a wider range of
doses.

can be used to quantify the approximate relative degree of cooperative binding of the test

agents to Na channels in nerve fibers. Values of
site for the test agents are present on Na channels.

greater than one may indicate more than one binding
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The evidence for multiple binding sites for LAs is mixed. Dose-response relations obtained from
lidocaine- and benzocaine-block of open Na channels (Wang et al. 2004) were both shown to exhibit Hill
slopes of 0.9 ± 0.1, suggesting that binding is not cooperative and binding likely occurs at a single site.
Leuwer et al. (2004) characterized the block of lidocaine and phenol derivatives on human skeletal muscle Na channels using a blocking model (modulated receptor model from Bean et al. 1983), where the
agents bound and blocked only closed and inactivated channels. They found that about two blocking
agents would have to bind inactivated Na channels to fit their model to data. However, it is not clear if
Leuwer et al. (2004) would have obtained the same conclusion had they used a model that permitted the
anesthetic agents to bind open, closed, and inactivated states.
Even if LAs can block Na channels at only one site, CAP block reflects the block of many different
APs exhibiting a range of conduction velocities. AP block is also non-linearly related to Na channel block;
about 75% of Na channels must be blocked to obtain 50% AP block when membrane APs and block are
modeled using the Hodgkin-Huxley equations. Agents that alter the Na channel kinetic properties also
contribute to AP block. In addition, the voltage dependence of Na channel opening is altered in the presence of local anesthetic agents and this will further complicate the relationship between Na channel block
and CAP block.
Kondratiev and Hahin (2001) and Hahin and Kondratiev (2001) showed that straight chain alcohols, between two and eight carbons long, block Na channels and CAPs. Logistic fits to dose-response
curves for all the alcohols blocking Na channels and CAPs were reasonably fit by a single value of

.

Kondratiev and Hahin (2001) also showed that the alcohols altered the kinetic and voltage-dependent
properties of Na channels to varying degrees depending on alcohol chain length, causing a reduction in
Na channel current that indicated channel block. The effects on kinetic and voltage-dependent properties
were fairly small or non-existent for the alcohols, suggesting that the alcohols block Na channels in a virtually identical manner. Therefore, the variability in

observed in the dose-response curves in this work

suggests that not all the test agents may block Na channels in an identical fashion.
group placement and number on the aromatic ring.

is altered by methyl
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The following least-squares regression model predicts

well (

This model suggests that CPs with smaller hydrophobicities, pKa’s, and
lecular volumes generally have larger
was no correlation found between

):

s and those with larger mo-

values and, hence, alter Na channels to a greater degree. There
and

when all test agents were regarded as a group. Neverthe-

less, it might be that that the position and arrangement of methyl groups in part

, as Table 3 shows that

varies as test agent structure varies. Within each group of CPs, namely the 1NXXCPs, 1NXCPs, 2NCPs, and 4mNmTPCP, there was variation in
of chemical structure on
among the 1NXCPs (

.

, which further complicates the determination of the effect

decreases as potency increases among the 1NXXCPs (

= 0.977) and

= 0.833), which might suggest that more potent test agents have wider therapeu-

tic ranges. All least-squares regression models were developed in Microsoft Excel 2010 and employed a
reductive approach, starting with a model including six polynomial powers of each predictor variable and
then reducing the number of variables one at a time.

1NXXCP Potency

Tonic blocking potency varied as methyl groups were effectively “added” onto the aromatic ring.
The addition of methyl groups to 1N2CP to either the fifth or sixth positions increased potency; in the latter case, potency more than doubled. Relative potency was maximized when the aromatic ring methyl
groups were separated by two positions, i.e., by one unsubstituted aromatic ring carbon; 1N26CP and
1N35CP have the largest potencies. The methyl group position in 1N3CP was the most effective in causing CAP block of all 1N-CPs (Table 3), but additions of methyl groups to 1N3CP reduced potency. The
addition of methyl substituents to 1N3CP to the fourth, fifth, or sixth positions decreased potency, in the
extreme case by nearly five-fold. Potency again was maximized when the methyl groups were separated
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by two positions. The shape of the aromatic ring moiety of the test agents, determined by the position and
arrangements of the methyl groups, plays a role in channel interactions.

Potency and Recovery

in Table 3 represents the degree of recovery from test agent block at the

concentra-

tion. Recovery represents the degree of CAP height recovery after the test agent is removed from the
nerve, and test agents with lower recoveries may tend to bind longer to channels and to the nerve and
may clear the body more slowly. Table 3 suggests that the position of the methyl groups among the
1NXXCPs and the 2N-CPs determines the degree of recovery.
creases (

increases as relative potency de-

0.909), which suggests that potent channel blockers are associated with small degrees of

recovery.
Just as

can be used to determine the relative potency of the test agents,

, or recovery,

may be used to determine the relative reversibility of binding of the test agents, which in turn might suggest relative toxicity. Bupivacaine and the 2N-CPs had the lowest recoveries, which suggests that the αamide linkage leads to smaller recoveries. af Ekenstam et al. (1957) found that the α-amide-based n-alkyl
pyrrolidine and n-alkyl piperidine carboxylic acid LAs synthesized, when compared with the β-amide and
the γ-amides, were the most potent and the most toxic, which might suggest that toxicity increases with
potency. Bupivacaine was shown not only to be associated with a small recovery, but also slow recovery.
Bupivacine dissociates about ten times slower from cardiac Na channels than lidocaine and does not dissociate quickly enough during diastole to cause complete ventricular AP recovery (Clarkson and Hodeghem, 1985). Lidocaine recovery from block is quicker and complete and there is little block accumulation at normal heart rates (Clarkson and Hodeghem, 1985). The rate of dissociation of bupivacaine from
neuronal Na channels is also ten times or more than lidocaine (Courtney et al. 1978).
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The results suggest that the 1NXCPs will exhibit the most rapid recovery from channel block and
likely exhibit the least cardiotoxicity, which makes them appear to have greater promise as useful and
safe putative LAs.

Phasic Block and Hydrophobicity

All 1N-CPs, except for 1N34CP, showed greater phasic blocking capability as frequency increased. The degree of phasic block increase from 10 pps to 20 pps varied considerably across all test
agents. The 1N-CPs are virtually permanently uncharged molecules, which, by the trapping hypothesis,
would suggest that these test should not show use-dependence. However, Table 6 shows that the uncharged nature of virtually all the CPs is not a determinant of phasic block potency. However, the CPs
were less effective in causing phasic block than bupivacaine and lidocaine.
Table 6 further suggests that the position of the methyl groups among the 1N-CPs does not determine phasic blocking capability. The 1NXXCPs exhibited larger degrees of phasic block than the
1NXCPs. The phasic blocking potencies of the 1NXCPs increased more than those of the 1NXXCPs as
stimulation rate increased. However, regardless of stimulation rate, the phasic blocking potency increased
when a methyl group was added to 1N2CP, 1N3CP, or 1N4CP to any position, suggesting increased hydrophobicity increases phasic block.

CPs Do Not Preferentially Block Open Channels

Inactivation causes Na channels to become non-conducting shortly after opening due to membrane depolarization. Scorpion α-toxins bind Na channels and cause them to open repeatedly during
membrane depolarizations by reducing transitions to the inactivated state. BmK 16(5) toxin acted to
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cause Na channels to open repeatedly to result in long lasting CAPs. The resulting prolonged CAPs represent a combination of toxin-modified APs and unmodified APs. The APs arising from the circumferential
periphery of the nerve were most likely altered by the toxin via diffusion from the solvent and contributed
to CAP prolongation, while APs from fibers in the interior of the nerve were less or not modified. Thus if a
test agent preferentially blocks open state channels, then the block of CAP duration should be greater
than the block of CAP height.
Bupivacaine and most of the test agents showed no difference in the degree of block of CAP
heights and CAP durations in α-toxin treated nerves. Lidocaine, 1N34CP, and 1N35CP, the latter two
having a methyl group at position 3, only blocked CAP durations more than CAP heights. Lidocaine’s
preferential block of the open state was expected, as it is an anti-arrhythmic agent. Additional CPs, such
as 1N23CP, 1N33CP, and 1N345CP, should be evaluated to determine if the methyl group at position 3
is involved in preferential block of the open state. Agents that block the Na channel open state significantly reduce the severity of a number of conditions involving ectopic and/or repetitive AP firing, such as long
QT syndrome, chronic pain, and convulsions.

Frog, Rat, and Human Na Channels

There were no significant differences in the tonic blocking potencies of bupivacaine, 1N34CP,
1N3CP, and 4mNmTPCP between frog and rat nerve. These observations suggest that the relative potencies of the test agents obtained from frog experiments will adequately reflect the relative potencies of
these test agents in rat. Furthermore, relative potency determinations made in rat peripheral nerve will
likely forecast the relative potencies of CPs for human peripheral nerve since rat Na channels display
strong sequence similarity to their human counterparts.
Rat and human alpha subunits of Nav3, present in dorsal root and trigeminal ganglia, show
strong (89%) primary sequence identity (Lu and Brown, 1998). The SCN3 gene, which codes for Na
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channels in central and peripheral neurons, is conserved in rats and humans (Lu and Brown, 1998). Also
there is a considerable degree of sequence identity between Na channels in rat and frog. SCN2A, which
codes for sodium channel protein type 2 subunit in humans, is conserved in rat and frog: relative to
SCN2A from Homo sapiens, the Na channel protein type 2 alpha-like subunit from Xenopus tropicalis
(western clawed frog) is 85.11% identical and SCN2A from Rattus norvegicus is 97.75% identical.
The open state molecular Na channel model of Lipkind and Fozzard (2005) suggested how amide
LAs lidocaine, etidocaine, mepivacaine, and bupivacaine dock with the channel to cause block. Lipkind
and Fozzard (2005) proposed that the tertiary amine portion of LAs interacted with the residues F1579 of
D4S6 and L1280 of D3S6 from human Nav1.4 and the LA aromatic moieties interacted with residues
Y1586 of D4S6 and N434 of D1S6. An alignment of Na channel protein type 2 alpha subunits from Homo
sapiens, Rattus norvegicus, and Xenopus tropicalis is shown below in Figure 33. This alignment shows
that, relative to the human subunit, the frog and rat subunits have, respectively, 85% and 98% sequence
identity. The following residues from human (h), rat (r), and frog (f) correspond with the residues Lipkind
and

Fozzard

(2005)

(LandF)L1280/hL1289/

(LandF)

indicate

rL1289/fI1289;

are

significant:

(LandF)F1579/hF1570/rF1570/fW1570;

(LandF)Y1586/hY1588/rW1588/fI1588;

and

(LandF)N434/hN432/rN432/fN432. These similarities between key interaction residues across the species
and the Lipkind-Fozzard model suggest that LAs will interact similarly with Na channels in all these species. Because of the similarities in rat and human Na channel genes, it is likely that relative potencies obtained in this work will be good predictors of relative potencies in human peripheral nerves.

rat
human
frog

Figure 33. Alignment of Na channel protein type 2 alpha subunits. “*” indicates the amino acid residues
are identical at that position. : indicates that conserved substitutions have been observed. “.” indicates
that semi-conserved substitutions have been observed. A blank indicates there is no match among the
residues. Letters and colors shown are used by ClustalX to designate amino acid residues.
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ED50 Estimation

Among 1N-CPs,

is completely predicted (

) as a function of pKa, molar volume

and methyl group positions on the aromatic ring using the following model, obtained using least-squares
regression analysis.

(5)

where

denotes the position of the first methyl group in the IUPAC name and

denotes the position of

the second methyl group in the IUPAC name of the test agent. Potency increases if the methyl groups are
further away from the amide nitrogen (e.g., if they are closer to positions 3 and 4), if pKa increases, and if
molar volume decreases. However, potency for the 2N-CPs are solely determined by pKa, as equation
(6) predicts

completely (

):

(6)
For 2N-CPs, potency increases if pKa decreases. Unlike the 1N-CPs, the placement of the methyl groups
on the aromatic ring and the molar volume are not significant predictors of the

for 2N-CPs. The 2N-

CPs were shown to be more potent than the 1N-CPs (Table 3). The presence of the α-amide linkage present in the 2N-CPs appears significant in increasing the ability of CPs to block CAPs. Consistent with these results, af Ekenstam et al. (1957) found that the α-amide linkage, such as those found in the 2N-CPs,
conferred greater potency, compared with the β- and γ-amide linkages. Equations (5) and (6) were used
to estimate the

s for the full range of possible 1NXXCPs, 1NXCPs, 2NXCPs, 2NXXCPs, and

2NXXXCPs, shown in Table 9.
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Table 9.
Model Estimates of ED50s.

vol = molar volume in mL; pKa = acid dissociation constant; log P = log octanol-water partition
coefficient;
= estimated
in mM. Chemical properties were estimated, when not given in
the literature, using SPARC.
1N-CPs

vol

pKa

log P

2N-CPs

vol

pKa

log P

1NCP
1N2CP
1N3CP
1N4CP
1N22CP
1N23CP
1N24CP
1N25CP
1N26CP

176.10
192.30
192.30
192.30
208.73
208.73
208.73
208.73
208.73

0.10
0.14
0.19
0.22
0.33
0.35
0.35
0.35
0.39

1.91
2.37
2.37
2.37
2.74
2.83
2.83
2.83
2.83

79.97
8.73
1.70
3.58
43.49
39.67
23.76
7.85
3.94

2NCP
2N2CP
2N3CP
2N4CP
2N22CP
2N23CP
2N24CP
2N25CP
2N26CP

204.27
197.30
197.30
197.30
222.80
213.60
213.60
213.60
213.60

8.44
8.60
8.60
8.60
8.90
8.60
8.60
8.60
8.60

1.37
1.83
1.83
1.83
1.59
2.29
2.29
2.29
2.29

4.42
3.27
3.27
3.27
1.30
3.27
3.27
3.27
3.27

1N33CP

208.73

0.35

2.74

23.16

2N33CP

222.00

8.90

2.54

1.30

1N34CP
1N35CP
1N44CP

208.73
208.73
208.73

0.43
0.39
0.39

2.83
2.83
2.68

8.63
3.34
2.74

2N34CP
2N35CP
2N44CP
2N223CP
2N224CP
2N225CP
2N226CP
2N233CP
2N234CP
2N235CP
2N236CP
2N244CP
2N245CP
2N246CP
2N255CP

213.60
213.60
222.00
238.90
238.90
238.90
238.90
238.90
238.90
238.90
238.90
238.90
238.90
238.90
238.90

8.60
8.60
8.90
8.90
8.90
8.90
8.90
8.90
8.60
8.60
8.60
8.90
8.60
8.60
8.90

2.29
2.29
2.54
2.18
2.18
2.18
2.18
3.13
2.75
2.75
2.75
3.13
2.75
2.75
3.20

3.27
3.27
1.30
1.30
1.30
1.30
1.30
1.30
3.27
3.27
3.27
1.30
3.27
3.27
1.30

2N256CP

238.90

8.60

2.75

3.27

2N266CP

238.90

8.90

3.20

1.30
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Potential Future Work

When compared to bupivacaine, novel LA candidates should be similarly potent and long-lasting,
but less toxic. Since the recovery from block of the 1N-CPs was greater than that of the 2N-CPs, the 1NCPs are potentially better novel candidates for LAs. However, since the 2N-CPs lack bupivacaine’s butyl
group, they may potentially be safer LAs than bupivacaine. The following CPs are recommended for future evaluation in rat toxicity and efficacy studies because of their marked potency: 1N3CP, 2N22CP,
2N33CP, 2N44CP, 2N223CP, 2N224CP, 2N225CP, 2N226CP, 2N233CP, 2N244CP, 2N255CP, and
2N266CP.
Experiments designed directly to test the tonic and phasic blocking action of CPs on Na channels
using the voltage-clamp can be used to verify the findings in this work. The single muscle voltage-clamp
(Campbell and Hille, 1976; Campbell and Hahin, 1984) can be used to assay CP block of skeletal muscle
Na channels. Whole cell recording voltage-clamp using the patch-clamp technique (Hamill and Sakmann,
1981) can be used to study CP block of human heart and other Na channel isoforms. If recombinant heart
Na channels (Wang et al. 2004) that can’t inactivate are used in whole-cell patch clamp experiments, then
CPs can be further tested for whether they preferentially block the open state of the Na channel. A number of the CPs are potential clinical local anesthetics. To obtain preliminary evidence for their potential
use, experiments must be performed to evaluate their efficacy, safety, and toxicity.
Equation (5) gives a wide range of estimated

s for the 1N-CPs, which supports the notion

that, for the 1N-CPs, the positions of the methyl groups is an essential determinant of

. Equation (6)

suggests that the potency of the 2N-CPs does not depend on the positions of the methyl groups, but only
on pKa, which results in much less variability in estimated

. The 1NXXXCPs, 3N-CPs, and 4N-CPs

were not considered in this work and must be evaluated experimentally to test equations (5) and (6) and
further expand on the current work.
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The CPs act similarly as bupivacaine while being uncharged at physiologic pH, but the CPs have
pKa values that are significantly less than bupivacaine, other LAs, and other drugs that are injected. Molecular charge was found not to be a significant factor for producing AP block, but the clinical manifestations of the significantly low pKa values of the CPs are currently unknown. Nevertheless, a number of
clinical drugs that are relatively acidic are currently used safely. For example, warfarin, used as an anticoagulant, has a pKa of 5.0 and is administered in the form of a sodium salt, as its free acid form is not
considerably water soluble. Other acidic drugs include the analgesic aspirin (pKa 3.5), antibiotic
cephalexin (pKa 3.6), the anticonvulsant Clonazepam (pKa 1.4), anti-inflammatory colchicine (pKa 1.7),
mast cell stabilizer Cromolyn (pKa 2.0), and coumarin derivative proxicromil (pKa 1.9). A significant fraction of acidic drugs are typically uncharged at physiologic pH and must be solubilized in acidic solution, as
is the case with the CPs.
Experiments using select CPs on live rats after in vitro analyses similar to those in this work to
determine their ability to alleviate pain would be the next step toward developing a novel set of LAs. The
physiologic effects of the low pKa of the CPs can be investigated by exposure the CPs and other drugs
that represent a range of pKa values to nerve and then perform histological analyses.
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